Results of postoperative radiotherapy in the treatment of uterine sarcomas: a retrospective analysis of 46 patients

Purpose: The aim of this study was to evaluate treatment outcome, survival data and prognostic factors in patients with uterine sarcoma treated by postoperative radiotherapy. Materials and Methods: The records of 46 patients treated between 1993 and 2003 were reviewed. Median age was 55 (range 31-75). There were 21 mixed mullerian tumors, 12 leiomyosarcomas, I I endometrial stromal sarcomas and two adenosarcomas. According to FIGO classification 65.2% were Stage 1, 17.4% Stage 11, 13% Stage III and 4.3% Stage IV. All patients received external radiotherapy with 1.8 Gy daily fractions up to 50.4-64 Gy (median 50.4 Gy). Intracavitary brachytherapy was applied to 39 patients. Twelve patients received adjuvant chemotherapy. Results: Median follow-up time was 48 months (6-144 months). Seventeen patients (37%) developed distant metastases and one patient had local failure. Five-year overall, disease-free and local recurrence-free survival rates were 57.8%, 60.5% and 97.8%, respectively. Univariate analysis demonstrated that stage (p = 0.011), histologic subtype (p = 0.010), tumor size (p = 0.044), positive peritoneal cytology (p = 0.006) and the use of chemotherapy (p = 0.005) had a significant effect on overall survival. Prognostic factors influencing disease-free survival were stage (p = 0.009), positive peritoneal cytology (p = 0.000) and the use of chemotherapy (p = 0.002). The only prognostic factor affecting local control was stage (p = 0.000). Conclusion: Postoperative radiotherapy seems to be an effective adjuvant treatment providing high local control rates in uterine sarcomas. However its efficacy should be clarified by randomized trials. The important prognostic factors influencing the treatment results were stage, histologic subtype, tumor size and positive peritoneal cytology.

Uterine sarcoma; Radiotherapy; Prognostic factors

[1] Olah K.S., Gee H., Blunt S., Dunn J.A., Kelly K., Chan K.K.: “Retrospective analysis of 318 cases of uterine sarconma”. Eur. J. Cancer, 1991, 27, 1095.

[2] Moskovic E., MacSweeney E., Law M., Price A.: “Survival, patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients”. Br. J. Radiol., 1993, 66, 1009.

[3] Marchese M.J., Liskow A.S., Crum C.P., McCaffrey R.M., Frick H.C., 2nd: “Uterine sarcomas: A clinicopathologic study, 1965- 1981”. Gynecol. Oncol., 1984, 18, 299.

[4] Livi L., Paiar F., Shah N., Blake P., Villanucci A., Amuni G. et al.: “Uterine sarcoma: twenty-seven years of experience”. Int. J. Radiat. Oncol. Biol. Phys., 2003, 57, 1366.

[5] Kelly K.L., Craighead P.S.: “Characteristics and management of uterine sarcoma patients treated at the Tom Baker Cancer Centre”. Int. J. Gynecol. Cancer, 2005, 15, 132.

[6] Hornback N.B., Omura G., Major F.J.: “Observations on the use of adjuvant radiation therapy in patients with Stage I and II uterine sarcoma”. Int. J. Radiat. Oncol. Biol. Phys., 1986, 12, 2127.

[7] Chauveinc L., Deniaud E., Plancher C., Sastre X., Amsani F., de la Rochefordiere A. et al.: “Uterine sarcomas: the Curie Institut Experience. Prognosis factors and adjuvant treatments”. Gynecol. Oncol., 1999, 72, 232.

[8] Hoffmann W., Schmandt S., Kortmann R.D., Schiebe M., Dietl J., Bamberg M.: “Radiotherapy in the treatment of uterine sarcomas. A retrospective analysis of 54 cases”. Gynecol. Obstet. Invest., 1996, 42, 49.

[9] Larson B., Silfversward C., Nilsson B., Pettersson F.: “Mixed mullerian tumours of the uterus-prognostic factors: a clinical and histopathologicstudyof147cases”. Radiother. Oncol., 1990, 17, 123.

[10] Knocke T.H., Kucera H., Dorfler D., Pokrajac B., Potter R.: “Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri”. Cancer, 1998, 83, 1972.

[11] Ferrer F., Sabater S., Farrus B., Guedea F., Rovirosa A., Anglada L. et al.: “Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Group Oncologic Catala-Occita”. Int. J. Radiat. Oncol. Biol. Phys., 1999, 44, 47.

[12] Riddle P.J., Echeta C.B., Manek S., Lavery B.A., Charnock F.M., Mackenzie I. et al.: “Retrospective study of management of uterine sarcomas at Oxford 1990-1998: role of adjuvant treatment”. Clin. Oncol. (R. Coll. Radiol.), 2002, 14, 54.

[13] Reed N.S., Mangioni C., Malmstrom H., Scarfone G., Poveda A., Tateo S. et al.: “First results of a randomised trial comparing radiotherapy versus observation postoperatively in patients with uterine sarcoma. An EORTC-GCG Study”. Int. J. Gynecol. Cancer, 2003, 13 (s1), 4.

[14] Giuntoli R.L. 2nd, Metzinger D.S., DiMarco C.S., Cha S.C., Sloan J.A., Keeney G.L. et al.: “Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy”. Gynecol. Oncol., 2003, 89, 460.

[15] Tinkler S.D., Cowie W.J.: “Uterine sarcomas: a review of the Edinburgh experience from 1974 to 1992”. Br. J. Radiol., 1993, 66, 998.

[16] Benoit L., Arnould L., Cheynel N., Goui S., Collin F., Fraisse J. et al.: “The role of surgery and treatment trends in uterine sarcoma”. Eur. J. Surg. Oncol., 2005, 31, 434.

[17] Piver M.S., Lele S.B., Marchetti D.L., Emrich L.J.: “Effect of adjuvant chemotherapy on time to recurrence and survival of Stage I uterine sarcomas”. J. Surg. Oncol., 1988, 38, 233.

[18] Sutton G., Brunetto V.L., Kilgore L., Soper J.T., McGehee R., Olt G. et al.: “A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2000, 79, 147.

[19] Tore G., Topuz E., Bilce N., Aslay I., Dincer M., Elgin A.: “The role of adjuvant chemotherapy in the treatment of uterine sarcoma patients”. Eur. J. Gynaecol. Oncol., 1990, 11, 307.

[20] Dinh T.A., Oliva E.A., Fuller A.F., Lee H., Goodman A.: “The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital”. Gynecol. Oncol., 2004, 92, 648.

[21] Major F.J., Blessing J.A., Silverberg S.G., Morrow C.P., Creasman W.T., Currie J.L. et al.: “Prognostic factors in early stage uterine sarcoma: a Gynecologic Oncology Group study”. Cancer, 1993, 71 (suppl.), 1702.

[22] Coquard R., Romestaing P., Ardiet J.M., Mornex F., Sentenac I., Gerard J.P.: “Uterine sarcoma treated by surgery and postoperative radiation therapy. Patterns of relapse, prognostic factors and role of radiation therapy”. Bull. Cancer, 1997, 84, 625.

[23] Brooks S.E., Zhan M., Cote T., Baquet C.R.: “Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999”. Gynecol. Oncol., 2004, 93, 204.

[24] Gerszten K., Faul C., Kounelis S., Huang Q., Kelley J., Jones M.W.: “The impact of adjuvant radiotherapy on carcinosarcoma of the uterus”. Gynecol. Oncol., 1998, 68, 8.

[25] Salazar O.M., Bonfiglio T.A., Patten S.F., Keller B.E., Feldstein M., Dunne M.E., Rudolph J.: “Uterine sarcomas: natural history, treatment and prognosis”. Cancer, 1978, 42, 1152.

[26] Echt G., Jepson J., Steel J., Langholz B., Luxton G., Hernandez W. et al.: “Treatment of uterine sarcomas”. Cancer, 1990, 66, 35.

[27] Callister M., Ramondetta L.M., Jhingran A., Burke T.W., Eifel P.J.: “Malignant mixed müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome”. Int. J. Radiat. Oncol. Biol. Phys., 2004, 58, 786.

[28] El Husseiny G., Al Bareedy N., Mourad W.A., Mohamed G., Shoukri M., Subhi J. et al.: “Prognostic factors and treatment modalities in uterine sarcoma”. Am. J. Clin. Oncol., 2002, 25, 256.

[29] Etiz D., Garipagaoglu M., Etiz E.E., Köse F.M., Kayikcioglu F., Haberal A. et al.: “Results of postoperative radiotherapy in the treatment of 29 uterine sarcoma patients”. Tumori, 2003, 89, 183.

[30] Olah K.S., Dunn J.A., Gee H.: “Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumors when adjusting for known prognostic factors: The results of a retrospective study of 423 cases of uterine sarcoma”. Br. J. Obstet. Gynaecol., 1992, 99, 590.

[31] Nordal R.R., Thoresen S.O.: “Uterine sarcomas in Norway 1956-1992: Incidence, survival and mortality”. Eur. J. Cancer, 1997, 33, 907.

[32] Evens H.: “Endometrial stromal sarcoma and poorly differentiated endometrial stromal sarcoma”. Cancer, 1980, 50, 2170.

[33] Yamada S.D., Burger R.A., Brewster W.R., Anton D., Kohler M.F., Monk B.J.: “Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus”. Cancer, 2000, 88, 2782.

[34] Hensley M.L., Maki R., Venkatraman E., Geller G., Lovegren M., Aghajanian C. et al.: “Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial”. J. Clin. Oncol., 2002, 20, 2824.

[35] Pautier P., Genestie C., Fizazi K., Morice P., Mottet C., Haie-Meder C. et al.: “Cisplatin based chemotherapy regimen (DECAV) for uterine sarcomas”. Int. J. Gynecol. Cancer, 2002, 12, 749.

[36] Toyoshima M., Akahira J., Matsunaga G., Niikura H., Ito K., Yaegashi N. et al.: “Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus”. Gynecol. Oncol., 2004, 94, 774.

[37] Wolfson A.H., Brady M.F., Rocereto T.F., Mannel R.S., Lee Y., Futoran R.J. et al.: “A Gynecologic Oncology Group randomized trial of whole abdominal irradiation versus cisplatin-ifosfamide+ mesna in optimally debulked Stage I-IV carcinosarcoma of the uterus”. J. Clin. Oncol., 2006, 24 (suppl.) 18S.

[38] Menczer J., Kravtsov V., Levy T., Berger E., Glezerman M., Avinoach I.: “Expression of c-kit in uterine carcinosarcoma”. Gynecol. Oncol., 2005, 96, 210.

[39] Raspollini M.R., Susini T., Amunni G., Paglierani M., Castiglione F., Garbini F. et al.: “Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?”. Int. J. Gynecol. Cancer, 2006, 16, 416.